Xstan Beta 40mg/25mg Tablet ER is a combination antihypertensive medication containing Telmisartan 40mg and Metoprolol Succinate 25mg in an extended-release formulation. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The extended-release formulation allows for once-daily dosing, promoting better patient compliance and stable plasma drug levels. Xstan Beta is indicated for the management of hypertension, particularly in patients who require dual therapy for optimal blood pressure control. It may also be beneficial in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure, where beta-blockade provides additional cardioprotective effects. Dosage adjustments should be individualized based on patient response and tolerability. Common adverse effects include dizziness, fatigue, and gastrointestinal disturbances. Contraindications include severe bradycardia, second- or third-degree atrioventricular block, and hypersensitivity to either component. Regular monitoring of blood pressure, renal function, and heart rate is recommended during therapy.